Zura Bio Limited (ZURA) - What Are Researchers Saying About This Stock?

Key Points

• Analysts are moderately bullish: Seven analysts give Zura Bio a “Moderate Buy” consensus, with five buy ratings, one strong buy, and one sell. The average 12-month price target is $17, well above the recent $4.04 share price.
• Recent performance remains weak: Shares trade below both their 50-day and 200-day moving averages and remain closer to the 52-week low of $3.25 than the high of $7.44. The company reported a quarterly loss of $0.20 per share, in line with expectations.
• Institutional ownership is substantial: Hedge funds and other institutions own 61.14% of Zura Bio, with several investors recently increasing their positions. The clinical-stage biotechnology company is developing immune-disease treatments, led by its investigational ZT-101 antibody.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $17.00.

A number of brokerages have weighed in on ZURA. Weiss Ratings raised shares of Zura Bio from a "sell (d-)" rating to a "sell (d)" rating in a report on Wednesday. Wedbush increased their target price on shares of Zura Bio from $15.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. Guggenheim reaffirmed a "buy" rating on shares of Zura Bio in a report on Friday. William Blair began coverage on Zura Bio in a research report on Wednesday, July 8th. They issued an "outperform" rating for the company. Finally, Wall Street Zen upgraded Zura Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 1st.

Zura Bio Price Performance

Zura Bio stock opened at $4.04 on Friday. Zura Bio has a fifty-two week low of $3.25 and a fifty-two week high of $7.44. The firm's 50 day simple moving average is $4.66 and its 200-day simple moving average is $5.24. The company has a market cap of $387.15 million, a P/E ratio of -3.61 and a beta of 0.01.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). On average, analysts expect that Zura Bio will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ZURA. Montanova Capital LLC raised its position in Zura Bio by 4.1% in the 2nd quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock worth $55,714,000 after purchasing an additional 376,000 shares during the last quarter. Siren L.L.C. increased its stake in shares of Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company's stock valued at $22,222,000 after buying an additional 2,434,866 shares during the period. Commodore Capital LP bought a new stake in shares of Zura Bio during the first quarter worth $19,338,000. Affinity Asset Advisors LLC raised its position in shares of Zura Bio by 41.4% during the first quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company's stock worth $15,258,000 after acquiring an additional 750,632 shares during the last quarter. Finally, EcoR1 Capital LLC acquired a new position in shares of Zura Bio during the first quarter valued at $7,019,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company's research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio's lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.